1. Research on anti-HIV drugs:
(1) Thomas Cech, the recent Nobel Prize winner and professor at the University of Colorado, USA, said: They are studying how to make anti-HIV drugs into missiles and guide them into cells. The precise target - HIV RNA. Once it hits its target, the antiviral agent splits the RNA in two and renders it harmless. They used this targeted ribozyme to complete experiments on mice to destroy the virus. Soon, they will conduct human trials.
(2) American scientists accidentally discovered in experiments that neomycin is the most effective antiviral drug among aminoglycosides to block the reproduction of HIV. Its action is to interfere with the sequence of virus proliferation. The final step of the activity causes the virus to collapse and be unable to continue to multiply. However, because neomycin has certain toxic and side effects, it is necessary to develop a preparation that has the same antiviral effect as neomycin and is less toxic.
(3) A British pharmaceutical company claims that an anti-cancer drug (EFB) they developed can kill human white blood cells infected with HIV in a test tube without harming normal cells. The potential of this drug to treat AIDS is currently being tested.
2. Research on drugs that block the binding of viruses to human cells:
(1) The Virus and Cellular Immunity Research Group of the Pasteur Institute in France has successfully developed a substance that destroys the molecular recognition function of CD26 protein, but it still needs Increase the "vitality" of this substance. The anti-AIDS drug will reportedly be ready for use in about two years.
(2) After 6 months of in vitro experiments, a research team from the French National Scientific Research Center found that the CD4 molecule can block the "entry" of lymphocytes, thereby preventing the HIV virus from invading normal cells, and has no effect on cells. Toxic side effects. In vivo tests in monkeys will soon be conducted.
(3) The Biochemistry and Protein Engineering Laboratory of the Scientific Research Center of the University of Marseille in France recently discovered a multi-head structure SPC molecule that can intervene when the HIV virus contacts the CD4 receptor to prevent the HIV virus from binding to cells. .
(4) Researchers at the University of Texas in the United States have used a protein contained in the HIV virus to make a drug, which effectively prevents the HIV virus from invading normal cells in vitro, but has not yet been tested in vivo.
3. Preparations to protect or restore immune function:
(1) A U.S. research team used human protein treatment of interleukin 12 to restore function to the immune systems of HIV-infected patients to prevent the development of AIDS. Only in vitro testing has been done, and human testing has begun.
(2) Biological response immunomodulatory drugs: Ecuadorian doctor Edwin Ceballos invented a new anti-AIDS drug BIRM, which is a biological response immunomodulatory drug. Analysis and tests by several laboratories in the United States have shown that it can prevent HIV from destroying the immune system. The Ecuadorian Medical Association endorsed all trial results. German and Swiss pharmaceutical companies have secured high-volume manufacturing rights and will soon be launching them on the market.
(3) Gene therapy: American scientist David Weiner conducted gene therapy experiments with mice, rabbits and monkeys, and the results were good. He implanted HIV genes into lymphoid tissue tumors, and then transplanted them into mice through lymphoid tissue tumors. After 40 days, antibodies and T lymphocytes appeared in the mice, indicating that the immune system had made an active resistance response to HIV. . Experimental results in rabbits show that the time required to generate an immune response is shorter than that in mice. Experiments on monkeys also achieved good results. Gene therapy based on genetic cells is highly praised by experts and is generally considered to be the "hope for the future" of AIDS treatment.